Unexpected Pulmonary Embolism Late After Recovery from Mild COVID-19?

  • Doranna De Pace Cardiology Division, Ospedale Unico Plurisede del VCO, Verbano-Cusio-Ossola, Italy
  • Sara Ariotti Cardiology Division, Ospedale Unico Plurisede del VCO, Verbano-Cusio-Ossola, Italy
  • Simone Persampieri Cardiology Division, Ospedale Unico Plurisede del VCO, Verbano-Cusio-Ossola, Italy
  • Giuseppe Patti Clinica Cardiologica, AOU Maggiore della Carità, Università del Piemonte Orientale, Novara, Italy
  • Lupi Alessandro Cardiology Division, Ospedale Unico Plurisede del VCO, Verbano-Cusio-Ossola, Italy

Keywords

SARS-CoV-2, COVID-19, thrombosis, inflammation, pulmonary embolism, direct oral anticoagulants

Abstract

SARS-CoV-2 infection is associated with an increased risk of venous thromboembolism (VTE), which is common during active illness but unusual in milder cases and after healing. We describe a case of bilateral acute pulmonary embolism occurring 3 months after recovery from a paucisymptomatic SARS-CoV-2 infection. The only VTE risk factor demonstrable was a history of previous SARS-CoV-2 infection, with laboratory signs of residual low-grade inflammation. Clinicians should be aware of VTE as a potential cause of sudden dyspnoea after COVID-19 resolution, especially in the presence of persistent systemic inflammation.

VIEW THE ENTIRE ARTICLE

References

  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
  • Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020;116(10):1666–1687.
  • Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19.Lancet 2020;395(10234):1417–1418.
  • Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020;20(7):389–391.
  • Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020;75(23):2950–2973.
  • Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135(23):2033–2040.
  • Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19.J Thromb Haemost 2020;18(7):1559–1561.
  • Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020;142(2):184–186.
  • Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148–150.
  • Dutch COVID & Thrombosis Coalition, Kaptein FHJ, Stals MAM, Grootenboers M, Braken SJE, Burggraaf JLI, van Bussel BCT, et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2021;199:143–148.
  • Vechi HT, Maia LR, Alves MDM. Late acute pulmonary embolism after mild coronavirus disease 2019 (COVID-19): a case series.Rev Inst Med Trop Sao Paulo 2020;62:e63.
  • Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol 2021;34(8):1456–1467.
  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034.
  • Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–147.
  • Assini A, Gandoglia I, Damato V, Rikani K, Evoli A, Del Sette M. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. Eur J Neurol 2021;28(10):3537–3539.
  • Nicol M, Cacoub L, Baudet M, Nahmani Y, Cacoub P, Cohen-Solal A, et al. Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. ESC Heart Fail 2020;7(6):4371–4376.
  • Taherifard E, Taherifard E, Movahed H, Mousavi MR. Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. Hematology 2021;26(1):225–239.
  • Nickel CH, Kellett J, Cooksley T, Lyngholm LE, Chang S, Imfeld S, et al. The diagnoses and outcomes of emergency patients with an elevated D-dimer over the next 90 days. Am J Med 2021;134(2):260–266.e2.
  • Mennuni MG, Renda G, Grisafi L, Rognoni A, Colombo C, Lio V, et al. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. J Thromb Thrombolysis 2021;52(3):782–790.
  • Published: 2021-12-21

    Issue: 2021: Vol 8 No 12 (view)

    Section: Articles

    How to cite:
    1.
    De Pace D, Ariotti S, Persampieri S, Patti G, Alessandro L. Unexpected Pulmonary Embolism Late After Recovery from Mild COVID-19?. EJCRIM 2021;8 doi:10.12890/2021_002854.